Explore All 9668 Add-on Acquisition Information Technology Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | December 19, 2014 |
| Target | Bina Technologies |
| Sector | Information Technology |
| Buyer(s) | Roche |
| Deal Type | Add-on Acquisition |
FILTER BY
| Category | Company |
|---|---|
| Founded | 1896 |
| Sector | Life Science |
| Employees | 100,920 |
| Revenue | 62.4B CHF (2024) |
Roche is a research-focused healthcare company focused on pharmaceuticals and diagnostics. Roche offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. It offers diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche was founded in 1896 and is based in Basel, Switzerland.
| Deal Context for Buyer | # |
|---|---|
| Overall | 22 of 44 |
| Sector: Information Technology | 2 of 2 |
| Type: Add-on Acquisition | 20 of 36 |
| State: California | 6 of 16 |
| Country: United States | 12 of 30 |
| Year: 2014 | 5 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-12-02 |
Ariosa Diagnostics
San Jose, California, United States Ariosa Diagnostics, Inc. is a global molecular diagnostics company committed to improving overall patient care by developing and delivering innovative, affordable, and widely-accessible testing services through their CLIA laboratory. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-01-16 |
Trophos SA
Marseille, France Trophos is a late stage clinical stage company with a pipeline of original molecules in development for neurological and cardiac diseases. These diseases include spinal muscular atrophy (SMA), Multiple Sclerosis (MS) disability progression and Cardiac Ischemia-Reperfusion Injury (IRI). Trophos additionally has collaborative research projects in other neurological conditions. |
Buy | €470M |
